1. 109TiPAcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types. (17th December 2018) Authors: Marabelle, A; Chevret, S; Janot, F; Escudier, B; Pouessel, D; Tournigand, C; Hoang-Xuan, K; Mortier, L; Rousseau, B J-C; Schlumberger, M J; Ray-Coquard, I L; Blay, J-Y; Niccoli, P; Jaccard, A; Couch, D; Hoog-Labouret, N; Pauporte, I; Massard, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. (4th October 2019) Authors: Moro-Sibilot, D; Cozic, N; Pérol, M; Mazières, J; Otto, J; Souquet, P J; Bahleda, R; Wislez, M; Zalcman, G; Guibert, S D; Barlési, F; Mennecier, B; Monnet, I; Sabatier, R; Bota, S; Dubos, C; Verriele, V; Haddad, V; Ferretti, G; Cortot, A Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗